Theralink Technologies is a precision oncology diagnostics company built around a single core product: the Theralink Assay, a lab test that uses Reverse Phase Protein Array (RPPA) technology to measure which proteins in a patient's tumor are activated and driving cancer growth. Unlike genomic tests that identify DNA mutations, the Theralink Assay directly measures activated protein signaling — the level at which most cancer drugs actually operate — helping oncologists determine which targeted therapies are likely to work for a given patient. The company's current commercial product is the Theralink Breast Cancer Assay, which Theralink processes at its single CLIA-certified, CAP-accredited lab in Golden, Colorado. Theralink generates revenue through two channels: billing Medicare and private payors per clinical test ordered by oncologists, and providing protein profiling services to biopharma companies under milestone-based R&D contracts. Most revenue to date has come from biopharma contracts, with clinical test volume growing as Medicare reimbursement ramps up. A key growth lever is expanding insurance coverage beyond Medicare to commercial payors, supported by obtaining a PLA billing code for a planned pan-tumor assay covering additional cancer types. Theralink also sees companion diagnostic partnerships — where its assay is formally linked to a specific drug's FDA approval — as a path to high-volume, systematic test ordering. The company is in early commercial stage, investing in direct sales, medical affairs, and outcomes studies to build clinical evidence and drive oncologist adoption.